Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05251701 · ClinicalTrials.gov registry record
Personal KinetiGraph® Clinical Validation Study
A clinical trial, sponsored by Global Kinetics Corporation.
- Completed
- Registry status
- 19
- Enrollment target
NCT05251701: Completed study, sponsored by Global Kinetics Corporation.
NCT05251701 is a clinical trial that has completed, run by Global Kinetics Corporation. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05251701 has completed, sponsored by Global Kinetics Corporation.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to clinically validate new measures of the Personal KinetiGraph® (PKG®).
Primary Outcome
The PKG's step detection system and manual step counts may be compared between healthy controls and person's with Parkinson's disease, while their walking is video recorded.
Interventions
- DEVICE Personal KinetiGraph® (PKG®) System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-12-09 |
| Est. Completion | 2025-09-03 |
What the finished NCT05251701 record still lists
NCT05251701 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Personal KinetiGraph® (PKG®) System is the first listed.
NCT05251701 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05251701 about?
NCT05251701 is a clinical study titled "Personal KinetiGraph® Clinical Validation Study". The purpose of this study is to clinically validate new measures of the Personal KinetiGraph® (PKG®).
What is the current status of trial NCT05251701?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2022-12-09. Estimated completion is 2025-09-03.
What interventions are being tested in trial NCT05251701?
The interventions under investigation include: Personal KinetiGraph® (PKG®) System (DEVICE).
Who is sponsoring clinical trial NCT05251701?
This trial is sponsored by Global Kinetics Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI